Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Discover Oncology|November 18, 2025
Induction chemotherapy followed by definitive chemoradiation in patients with inoperable esophageal squamous cell carcinoma: a multicenter retrospective studyTaha Koray Sahin, Imdat Eroglu, Ismail Dilli, et al.Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|September 30, 2016
Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experienceFurkan Sarici, Taner Babacan, Hakan Buyukhatipoglu, et al.Tumori|May 9, 2015
Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancerTaner Babacan, Orhan Efe, Ahmet S Hasirci, et al.Future Oncology (London, England)|February 8, 2024
Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancerCengiz Karacin, Veli Sunar, Zuhat Urakci, et al.Experimental Hematology & Oncology|June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerTaha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.Anti-Cancer Drugs|March 31, 2025
Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group studySelin Akturk Esen, Ismet Seven, Gonca Akdere Ates, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 1, 2024
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology GroupArif Akyildiz, Melis Gultekin, Ecem Yigit, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Efficacy of cumulative cisplatin dose on survival in patients with locally advanced cervical cancer treated with definitive chemoradiotherapy: multicenter study by Turkish Oncology GroupArif Akyildiz, Melis Gultekin, Ecem Yigit, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.Clinical Genitourinary Cancer|April 16, 2024
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, et al.Pageof 5